Title
Category
Credits
Event date
Cost
Improving Clinical Trial Accrual: Doing More with Less
  • Best Practices
  • 0.50 AAPA Category 1 CME credit
  • 0.50 ACPE contact hours
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 ANCC contact hours
  • 0.50 Participation
$0.00
Traditional recruitment to clinical trials was accomplished by outreach from the treating physician or staff associated with the clinical trial. It is important for clinicians to be aware of the logistics and the value that a clinical trial matching tool can bring to presenting a person with cancer the appropriate clinical trial.
Expanding the Reach of Clinical Trials
  • Best Practices
  • 0.75 AAPA Category 1 CME credit
  • 0.75 ACPE contact hours
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 ANCC contact hours
  • 0.75 Participation
$0.00
Although we have made some progress in ways of increasing clinical trial access to underserved communities, inequities persist. Education in this area is important because increasing access to clinical trials will have a positive impact on patient outcomes and help address current disparities in cancer treatment.
Innovative Strategies to Improve Patient Access
  • Best Practices
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
$0.00
Technology advancements in recent years have created many opportunities for improving patient access, including opportunities for self-scheduling. As practices are investing significant resources in this space it is important to understand the challenges, limitations, and impacts of these innovative approaches to solving patient access issues.
Reducing Intersectional Stigmas to Improve Outcomes in People Impacted by Cancer
  • Best Practices
  • 0.75 AAPA Category 1 CME credit
  • 0.75 ACPE contact hours
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 ANCC contact hours
  • 0.75 Participation
$0.00
Intersectional stigmas in cancer care can exacerbate disparities by compounding the challenges faced by individuals who belong to multiple marginalized groups, leading to inequities in access, treatment, and outcomes. There is often a lack of consistent implementation of screening and support services that address the unique needs of marginalized patients, resulting in disparities in early detection, treatment, and follow-up care.
Preparing the Oncology Nursing Workforce: Innovative Strategies and Partnerships
  • Best Practices
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
$0.00
With the increasing complexity of cancer care and the growing population of cancer patients, the need for skilled oncology nurses is more crucial than ever. Ensuring that oncology nurses are equipped with the necessary skills and knowledge is essential for providing high-quality care and improving patient outcomes.
From Theory to Practice: Building Sustainable, High-Impact Patient Navigation Models
  • Best Practices
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
$0.00
Patient navigation is highly variable; therefore, it is important to understand the factors that contribute to program success. It is also timely given the expansion of reimbursement for these types of services, as programs are looking at the sustainability of their programs and examining ways to better build or refine existing services.
Effective and Safe Telehealth Delivery and Remote Patient Monitoring
  • Best Practices
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
$0.00
In a continuous effort to provide cost-effective, high-quality oncology care, varying degrees of telehealth delivery and remote patient monitoring are being piloted or have been implemented. Exploring this topic is a valuable exercise to help the oncology care team know what is currently being done and what is on the horizon.
The Impact of Frontline Immune Checkpoint Inhibitors on Therapy for Relapsed/Refractory Hodgkin Lymphoma
  • Hodgkin Lymphoma
  • 0.75 AAPA Category 1 CME credit
  • 0.75 ACPE contact hours
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 ANCC contact hours
  • 0.75 Participation
$0.00
The treatment landscape for relapsed/refractory Hodgkin lymphoma has changed significantly in recent years with the incorporation of novel agents such as brentuximab vedotin and the checkpoint inhibitors nivolumab or pembrolizumab. Second-line and subsequent therapy decisions are complex and must take into account multiple factors, such as use of novel agents in the frontline setting and the potential unique toxicities of novel agents.
Updates in the Multidisciplinary Approach for Resectable Gastroesophageal Adenocarcinoma and Peritoneal-Limited Disease
  • Gastric/Esophageal Cancer
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
$0.00
The treatment landscape for gastroesophageal tumors is expanding, including the role of systemic therapy plus surgery. It is essential for healthcare professionals (HCPs) in community and academic settings to be aware of and understand current and emerging treatment options and associated evidence, even that which is limited and may be controversial.
Management of Advanced Gastroenteropancreatic Neuroendocrine Tumors
  • Neuroendocrine Tumors
  • 0.75 AAPA Category 1 CME credit
  • 0.75 ACPE contact hours
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 ANCC contact hours
  • 0.75 Participation
$0.00
As there are no data to support a specific sequence of regional versus systemic therapy or to guide sequencing of systemic therapy options, it is important for physicians to be aware of the available treatment options and emerging data on novel therapies so they can provide individualized care for their patients.

Pages